BMS drops HCV drug after death
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has discontinued development of BMS-986094 (BMS-094, formerly known as INX-189). The nucleotide polymerase (NS5B) inhibitor, which was in Phase II development for the treatment of hepatitis C, was the driver behind BMS' $2.5 billion acquisition of Inhibitex at the start of this year (scripintelligence.com, 9 January 2012).